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poptosis or programmed cell death plays a pivotal
role in embryonic development and maintenance
of homeostasis. It is also involved in the etiology of
pathophysiological conditions such as cancer, neurode-
generative, autoimmune, infectious, and heart diseases.
Consequently, the study of apoptosis is now at center of
both basic and clinical research applications. Therefore,
 
sensitive and simple apoptosis detection techniques are
required. Here we describe a monoclonal antibody–defined
A
 
novel antigen, namely 
 
NAPO
 
 (negative in apoptosis),
which is specifically lost during apoptosis. The anti-
 
NAPO
 
antibody recognizes two nuclear polypeptides of 60 and
70 kD. The antigen is maintained in quiescent and senescent
 
cells, as well as in different phases of the cell cycle, including
mitosis. Thus, immunodetection of 
 
NAPO
 
 antigen provides
a specific, sensitive, and easy method for differential
identification of apoptotic and nonapoptotic cells.
 
Introduction
 
During the last decade, apoptosis has become a major focus of
interest for many fields of biomedical research. Programmed
cell death is required for proper embryonic development as
well as for the maintenance of homeostasis in adult tissues
(Vaux and Korsmeyer, 1999; Wyllie and Golstein, 2001).
Moreover, apoptosis is involved in the etiology and patho-
physiology of a variety of diseases, such as cancer, neuro-
degenerative, autoimmune, infectious, and heart diseases
(Chervonsky, 1999; Roulston et al., 1999; Mattson, 2000;
Narula et al., 2000; Reed, 2000). Apoptotic cell death is
characterized by a series of morphological changes, including
cell shrinkage, nuclear condensation, chromatin segregation,
membrane blebbing, formation of membrane-bound apoptotic
bodies, and internucleosomal DNA cleavage (Saraste and
Pulkki, 2000). These morphological changes result from
a series of genetically programmed biochemical changes
initiated by either the activation of death receptors or in-
tracellular stress conditions such as DNA damage. These
proapoptotic signals are conveyed to mitochondria to cause
the release of caspase-activating factors from this organelle,
followed by a cascade of caspase activation which leads to
cell death (Earnshaw et al., 1999; Gottlieb, 2000).
Apoptosis, as a critical component of life in multicellular
organisms, is a target subject for understanding cellular
mechanisms of many diseases, as well as for developing new
drugs that interfere with either proapoptotic or antiapoptotic
molecular networks. Consequently, it has become important
to develop reliable assays to measure cell death. Techniques
currently available for apoptosis detection are based on the
study of morphology of apoptotic cells (light and fluores-
cence microscopy coupled to nuclear staining with specific
dyes and electron microscopy), DNA fragmentation detected
by terminal transferase-mediated dUTP nick-end labeling
(TUNEL)* and similar techniques, membrane changes
detected by annexin V in vivo labeling, and on immunological
assays using antibodies directed to apoptosis-related proteins
(Stadelmann and Lassmann, 2000). Essential requirements
for apoptosis detection techniques include high sensitivity
for apoptotic cells, the ability to differentiate between
apoptosis and other forms of cellular changes, as well as
distinction between different stages of the cell death process.
However, we are facing a relative paucity for simple tech-
niques fulfilling these requirements, and furthermore allowing
quantitative analysis (van Heerde et al., 2000). Immunological
detection of apoptosis-related proteins is probably the best
approach to overcome this obstacle, but there are only a few
known apoptosis marker antigens (Stadelmann and Lass-
mann, 2000).
Here we describe a mouse monoclonal antibody–defined
nuclear antigen composed of two polypeptides that we call
 
NAPO
 
 (for negative in apoptosis), which is strongly expressed
in cells under many conditions (proliferation, quiescence, mi-
tosis, and senescence) except apoptosis. The immunoreactivity
of the antigen, as tested by immunofluorescence technique,
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is lost in apoptotic cells in a way opposite to TUNEL and
annexin V staining. Thus, 
 
NAPO
 
 antigen may serve as a reli-
able marker for apoptosis.
 
Results and discussion
 
Biochemical characterization of the 
 
NAPO
 
 antigen
 
A mouse IgG monoclonal antibody (named anti-
 
NAPO
 
 an-
tibody) was generated against a nuclear antigen after immu-
nization with human colorectal cell line COLO 320. Deter-
gent-soluble proteins were prepared from metabolically
labeled Huh7 cells and subjected to immunoprecipitation
with anti-
 
NAPO
 
 antibody. As shown in Fig. 1 A, anti-
 
NAPO
 
 antibody recognized two proteins migrating at 
 

 
60
and 70 kD, respectively. Immunofluorescence studies re-
vealed with the same cell line indicated that 
 
NAPO
 
 was a
nuclear antigen (Fig. 1, B and C). This antibody was specific
for human and monkey 
 
NAPO
 
, since all human cell lines
and monkey COS-7 showed positive immunostaining, but
mouse (HC 11), rat (IAR-6), and hamster (CHOK-I) cell
lines were negative (unpublished data).
Although 
 
NAPO
 
 antigen was ubiquitously present in all
human cell lines so far tested, small nuclear fragments which
are occasionally observed with some cell lines under normal
culture conditions were negative (Fig. 1, D and E as an ex-
ample). This suggested to us that 
 
NAPO
 
 antigen could be
lost during apoptosis.
 
Identification of 
 
NAPO
 
 as an apoptotic marker
 
Hepatocellular carcinoma–derived SNU 398 cells, which
undergo apoptosis when grown under serum-free conditions
were serum starved for three days and tested for 
 
NAPO
 
 anti-
gen immunoreactivity. Cells displaying morphological char-
Figure 1. Initial characterization of NAPO antigen. Anti-NAPO 
monoclonal antibody recognizes two bands migrating at 60 and 
70 kD. [35S]methionine-labeled Huh7 cells were subjected to 
immunoprecipitation with anti-NAPO antibody (). () is a 
negative control (A). Immunofluorescence staining of Huh7 cells 
with anti-NAPO antibody indicates that NAPO is a nuclear antigen 
(B). Hoechst 33258 counterstain for nuclear DNA (C). NAPO 
immunofluorescence staining of SNU 398 cells growing in standard 
culture medium indicates that the majority of cell nuclei are 
positive, but occasionally some cells with small nuclei (presumably 
apoptotic) are negative (D), as indicated by white arrows in nuclear 
DNA staining (E). NAPO antigen is negative in apoptotic SNU 398 
cells which are induced by growth in serum-free medium (F). 
Apoptotic cells are indicated by white arrows in Hoechst 33258 
counterstaining (G).
Figure 2. Identification of NAPO as a common apoptosis marker. 
NAPO is negative in 100 M H2O2-treated apoptotic Huh7 cells 
(A), in contrast to positive staining with TUNEL (C). NAPO is also 
lost in Fas-mediated apoptosis in Jurkat cells (E), H2O2-mediated 
apoptosis in 293 cells (G), and UV-C–mediated apoptosis in MRC-5 
cells (I). B, D, F, H, and J show Hoechst 33258 counterstaining.
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acteristics of apoptosis (cell shrinkage, nuclear condensation,
and fragmentation) displayed negative 
 
NAPO
 
 staining in
contrast to positive nuclear staining of all nonapoptotic cells
(Fig. 1, F and G).
To confirm the loss of 
 
NAPO
 
 antigen during apoptosis in
another cellular system, hepatocellular carcinoma–derived
Huh7 cells were used. H
 
2
 
O
 
2
 
 (100 
 

 
M) treatment of these
cells induce apoptosis under serum-deficient (0.1% FCS)
conditions (unpublished data). As shown in Fig. 2 A, 
 
NAPO
 
antigen was negative in apoptotic Huh7 cells that are identi-
fied as cells with small nuclei by Hoechst 33258 counter-
staining (Fig. 2 B). To test whether the loss of 
 
NAPO
 
 expres-
sion is specific to this antigen, rather than a common feature
shared by nuclear proteins, we also tested Huh7 cells for p53
protein immunoreactivity under similar conditions. Huh7
cells express a mutant p53 protein that accumulate in their
nuclei (Volkmann et al., 1994). Both apoptotic and nonap-
optotic Huh7 cells displayed positive staining for p53 protein.
Indeed, apoptotic cells displayed a stronger p53 immunore-
activity when compared with nonapoptotic cells (unpub-
lished data). This indicated that the loss of 
 
NAPO
 
 immu-
noreactivity in apoptotic Huh7 cells was specific to this
antigen rather than a common feature of nuclear proteins.
For further characterization of NAPO as an apoptosis
marker, additional studies were performed in different cell
lines treated with different apoptosis stimuli. For all experi-
ments NAPO tests were run in parallel to TUNEL or an-
nexin V staining (TUNEL data for Huh7 shown in Fig. 2 C
as an example). To show whether NAPO antigen is lost dur-
ing death receptor–mediated apoptosis, TNF-
 

 
–treated
MCF 7 and anti-Fas antibody–treated Jurkat cells were used.
NAPO was lost in apoptotic Jurkat (Fig. 2 E) as well as
MCF-7 cells (unpublished data). To test whether 
 
NAPO
 
 loss
during apoptosis was common to cells of different origin, ad-
ditional tumor-derived (HeLa, U2OS, A375, SW480, LN-
CaP) as well as normal tissue–derived (293 and MRC-5) cell
lines were induced to undergo apoptosis by H
 
2
 
O
 
2
 
, UV-C, or
cisplatin treatment (Table I). NAPO staining was lost in all
apoptotic cells in contrast to strong nuclear staining of the
nonapoptotic counterparts (example data on 293 and MRC-5
cells are shown in Fig. 2, G and I, respectively).
These results demonstrate that NAPO is ubiquitously ex-
pressed in living cells, but lost during apoptosis independent
of the apoptosis activating pathway (Table I). The loss of
 
NAPO
 
 during apoptosis strongly suggests that this antigen is
a nuclear caspase substrate. The epitope recognized by anti-
 
NAPO
 
 antibody on this antigen is probably lost as a result of
caspase-mediated protein cleavage. However, it is presently
unclear whether any of 60- and 70-kD polypeptides of the
 
NAPO
 
 antigen are known caspase substrates. To our knowl-
edge, proteins with similar molecular weight have not been
described previously as apoptosis-associated proteins. Thus,
 
NAPO
 
 appears to be a novel marker for apoptosis that could
serve to distinguish apoptotic from nonapoptotic cells. How-
ever, it was important to know whether the antigenic reactiv-
ity is modified under different growth conditions such as
quiescence, cell cycle (especially mitosis), and senescence.
 
Expression of the 
 
NAPO
 
 antigen in quiescent cells
 
MRC-5 human embryonic lung fibroblast cells (passage 18)
were grown to confluency and serum starved for 3 d to in-
duce quiescence. To show that these cells are indeed quies-
cent, BrdU incorporation was also tested. Our results indi-
cate that 
 

 
15% of asynchronously growing MRC-5 cells are
positive for BrdU i.e., in S phase (Fig. 3 A), whereas no
BrdU labeling was observed in quiescent cells (Fig. 3 E).
Under both conditions, all cells displayed a similarly positive
nuclear staining for 
 
NAPO
 
 (Fig. 3, C and G). These obser-
 
Table I. 
 
List of cell lines tested for loss of 
 
NAPO
 
 immunoreactivity 
after induction of apoptosis by various stimuli
Cell line Origin Morphology Apoptosis stimuli
 
Huh 7 HCC Epithelial H
 
2
 
O
 
2
 
SNU 398 HCC Epithelial Serum starvation
MCF7 Breast cancer Epithelial TNF-
 

 
, UV-C 
HeLa Cervix cancer Epithelial UV-C
SW480 Colon cancer Epithelial UV-C
LNCaP Prostate cancer Epithelial UV-C
U2OS Osteosarcoma Epithelial UV-C
A375 Melanoma Epithelial UV-C
Jurkat TCL Lymphoid Anti-Fas, UV-C
MRC-5 Lung Fibroblastic UV-C
293 Embryonal kidney Epithelial Cisplatin, H
 
2
 
O
 
2
 
HCC, hepatocellular carcinoma; TCL, acute T cell leukemia.
Figure 3. NAPO antigen is positive in quiescent cells. MRC-5 cells 
were tested in parallel for BrdU incorporation (A and E) or NAPO 
antigen (C and G). Cells in A–D were grown under standard culture 
conditions. Cells in panels E–H were serum starved for 3 d to induce 
a quiescent state, as indicated by negative BrdU staining in E. Note 
that both actively growing (C) and quiescent cells (G) are positive 
for NAPO. B, D, F, and H show Hoechst 33258 counterstaining.
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vations indicated that 
 
NAPO
 
 expression is not lost in nondi-
viding quiescent cells.
 
Expression of the 
 
NAPO
 
 antigen during cell cycle
 
We also analyzed the expression pattern of 
 
NAPO
 
 in syn-
chronized cells in order to follow its positivity during differ-
ent phases of the cell cycle. For this purpose Huh7 cells were
treated with nocodazole and mitotic cells were collected by
mitotic shake-off and plated onto coverslips. Synchronized
Huh7 cells were tested every 4 h for 36 h of culture for both
BrdU incorporation and 
 
NAPO
 
 staining. BrdU incorpora-
tion was minimal until 16 h after the release from mitotic ar-
rest with a maximum of BrdU incorporation at 24 h, fol-
lowed by a significant decrease at 36 h (Fig. 4 A). According
to BrdU incorporation index, cells at time points before 16 h
were evaluated as G1 phase cells, cells between time points
20 and 32 h as S phase cells, and those at time point 36 h as
G2 phase cells. Mitotically arrested cells showed a diffusely
positive (nuclear and cytoplasmic) 
 
NAPO
 
 staining (Fig. 4 B).
 
NAPO
 
-staining pattern was nuclear throughout the cell cy-
cle, at all time points (time points 8, 24, and 36 h are shown
in Figs. 4, D, F, and H, respectively). Thus, 
 
NAPO
 
 staining
was always positive during the cell cycle, the only noticeable
change being a diffuse staining during mitosis, in contrast to
strictly nuclear staining in other phases of the cell cycle.
 
Expression of the 
 
NAPO
 
 antigen in senescent cells
 
To test whether 
 
NAPO
 
 antigen expression is modified dur-
ing senescence, MRC-5 cells were grown until passage 40, at
which point they remain alive and attached to cell plate, but
they stop dividing, a characteristic feature of senescence
(Fulder and Holliday, 1975).The senescence is often accom-
panied by a positive SA-
 

 
-gal activity, which is negative in
presenescent cells (Dimri et al., 1995). As shown in Fig. 5,
in contrast to presenescent MRC-5 cells at passage 18 (Fig.
5 A), senescent MRC-5 cells at passage 40 were positive
for SA-
 

 
-gal activity (Fig. 5 B). Immunofluorescence data
shown in Fig. 5, C and D, indicated that both presenescent
and senescent MRC-5 cells were positive for 
 
NAPO
 
 antigen
immunoreactivity, demonstrating that 
 
NAPO
 
 expression is
not lost in senescent cells.
Our observations demonstrate that 
 
NAPO
 
 is present in liv-
ing cells in all phases of the cell cycle as well as during senes-
cence and quiescence, getting lost only during apoptosis.
When compared with other available apoptosis detection sys-
tems, 
 
NAPO
 
 test is highly specific for apoptosis and offers the
simplicity of antibody-based assays. The anti-
 
NAPO
 
 anti-
body can be used for detection of apoptotic cells under differ-
ent conditions, such as in situ staining of cells and tissue sec-
tions, and for flow cytometry. TUNEL assay (Gavrieli et al.,
1992) is widely used for the identification of apoptotic cells,
even though it requires several cumbersome experimental
steps. As 
 
NAPO
 
 and TUNEL assays provide exclusive nuclear
staining of alive and apoptotic cells, respectively, we believe
that both assays may be combined for better identification of
apoptosis. Moreover, 
 
NAPO
 
 assay may detect apoptotic cells
before DNA fragmentation and it does not require special
pretreatment of assay samples. 
 
NAPO
 
 may also be used in
combination with annexin V staining (Martin et al., 1995).
 
NAPO
 
 differs from previously identified and antibody-
defined apoptosis markers (Grand et al., 1995; Zhang et al.,
1996; Hammond et al., 1998; Srinivasan et al., 1998; Leers
et al., 1999) by its exclusive loss in apoptotic cells, but not in
quiescent, proliferating, senescent, or even mitotic cells. We
believe that this antibody will be very helpful for develop-
ment of simple and easy immunoassays for measurement of
apoptosis in both cell lines and tissue samples.
 
Materials and methods
 
Monoclonal antibody production
 
10,000,000 COLO 320 cells were lysed in 2 ml PBS and 0.5 ml of lysate
was injected into tail vein of Balb/c mice. 1 mo later, mice were immu-
nized twice more at 1 wk intervals, hybridomas were prepared from
splenic cells, and antibody-producing clones were selected as described
previously (Ozturk et al., 1989). One of the antibodies of IgG isotype,
named anti-
 
NAPO, 
 
was used for further studies.
Figure 4. NAPO expression during cell cycle. Huh7 cells were 
synchronized by nocodazole treatment, followed by mitotic shake-
off. Freshly collected cells were then grown in culture for up to
36 h. The S phase was identified by BrdU incorporation assay. Time 
points between 0–16, 20–32, and 36 h were evaluated respectively 
as G1, S, and G2 phases according to the BrdU incorporation index 
(A). NAPO and BrdU staining were performed at 4 h intervals. B, D, 
F, and H illustrate NAPO staining of cells at mitotic arrest (B), 8 h 
(D), 24 h (F), and 36 h (H), respectively. C, E, G, and I show 
Hoechst 33258 counterstaining. Note diffused NAPO staining in 
mitotically arrested Huh7 cells (B and C) which were digitally 
magnified threefold for better visualization.
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Tissue culture
 
Huh7, SNU 398, COLO 320, MCF-7, HeLa, U2OS, SW480, A375, 293,
MRC-5, COS7, IAR-6, and CHOK-I cells were grown in DME (Biochrome
or GIBCO BRL). HC11 was grown in RPMI 1640 (Biological Industries)
supplemented with 10 ng/ml EGF (Sigma-Aldrich) and 5 
 

 
g/ml insulin
(Sigma-Aldrich). Jurkat and LNCaP cells were grown in RPMI 1640. All
cells were grown in media supplemented with 10% FCS, 1% nonessential
amino acids, 100 
 
g/ml penicillin/streptomycin at 37C and 5% CO2.
Induction of apoptosis
Apoptotic cell death was induced by either serum starvation or treatment
with H2O2, UV-C, cisplatin, anti-Fas antibody or TNF- treatment. SNU
398 hepatocellular carcinoma cells were induced in serum-free medium
for 3 d and tested for apoptosis. For oxidative stress–induced apoptosis,
Huh7 cells were incubated in a culture medium containing 0.1% FCS for
72 h, and treated with freshly prepared 100 M H2O2 for at least 4 h be-
fore apoptosis assay. 293 cells were treated with 200 M H2O2 or 100 M
cisplatin. MCF-7, HeLa, U2OS, A375, SW480, LNCaP, Jurkat, and MRC-5
cells were treated with UV-C irradiation (60–120 mJ/cm2). For physiologi-
cally induced apoptosis studies, TNF-–treated (Boehringer; 50 ng/ml for
72 h) MCF-7 and anti-fas antibody–treated (Upstate Biotechnology; clone
CH11, 25 ng/ml for 24 h) Jurkat cells were used.
Induction of quiescence
Presenescent MRC-5 cells (passage 18) were grown to confluency on cov-
erslips and serum starved for 3 d. At the end of 3 d, one set of cells was
tested for BrdU labeling and the other set was subjected to immunofluores-
cence for the expression of the NAPO antigen as described later. Asynchro-
nously growing MRC-5 cells of the same passage were used as a control.
Mitotic arrest and cell cycle synchronization
Huh7 cells were grown to 60% confluency and incubated with 50 ng/ml
nocodazole (Sigma-Aldrich) for 18 h. Mitotic cells were collected by mi-
totic shake-off and replated onto coverslips. At indicated time points (be-
tween 4 and 36 h), one set of cells was tested for BrdU labeling, and the
other set was subjected to immunofluorescence for the expression of the
NAPO antigen.
Immunoprecipitation
Huh7 cells grown to 70% confluency were starved in DME lacking me-
thionine (Sigma-Aldrich) and labeled with 200 Ci [35S]methionine (Amer-
sham Pharmacia Biotech) per 4 ml medium for 2 h. Cells were scraped in
ice-cold PBS and lysed in NP-40 lysis buffer (150 mM NaCl, 1.0% NP-40,
50 mM Tris pH 8.0, protease inhibitor cocktail; Roche), and centrifuged at
13,000 rpm at 4C for 30 min. The cell lysate was incubated with anti-
NAPO antibody for 2 h and the NAPO antigen was immunoprecipitated
by using protein G sepharose (Amersham Pharmacia Biotech).
Immunofluorescence
Cells were grown on coverslips and fixed with 100% ice-cold acetone for
1 min or by 4% paraformaldehyde for 1 h. When paraformaldehyde was
used, cells were permeabilized for 3 min with 0.1% Triton X-100 in 0.1%
sodium citrate. After saturation with 3% BSA in PBS-T (0.1%) for 15 min,
fixed cells were incubated with anti-NAPO antibody for 1 h at room tem-
perature. FITC-conjugated goat anti–mouse antibody (Dako) was used as
the secondary antibody and diluted as recommended by the supplier. The
immunofluorescence staining of Huh7 cells for p53 protein was tested us-
ing 6B10 monoclonal antibody (Yolcu et al., 2001). Nuclear DNA was vi-
sualized by incubation with 3 g/ml Hoechst 33258 (Sigma-Aldrich) for 5
min in the dark. Cover slips were then rinsed with distilled water, mounted
on glass microscopic slides in 50% glycerol, and examined under fluores-
cent microscope (ZEISS). Jurkat cells were cytospinned (Shandon) for 3
min at 200 rpm before immunofluorescence procedures.
TUNEL and annexin V stainings
The TUNEL assay was performed using an in situ cell death detection kit
(Roche), according to manufacturer’s recommendations. The annexin V
assay was performed by annexin V-PE reagent (PharMingen), according to
manufacturer’s recommendations, and cells were fixed in ethanol. After
TUNEL and annexin V assays, cells were counterstained with Hoechst
33258 and examined as described.
BrdU labeling and identification of S phase cells
For BrdU incorporation, cells were incubated with 30 M BrdU for 1 h be-
fore fixation with ice-cold 70% ethanol for 10 min. After DNA denatur-
ation in 2 N HCl for 20 min, cells were incubated with FITC-conjugated
anti-BrdU antibody (Dako) in the dilution as recommended by the sup-
plier, cells were counterstained with Hoechst 33258 and examined as de-
scribed.
Senescence-associated -galactosidase assay
MRC-5 cells were grown to passage 40 and subjected to senescence-asso-
ciated -galactosidase (SA -gal) assay, as described by Dimri et al.
(1995). Briefly, cells were fixed in 3% formaldehyde for 5 min and incu-
bated with SA -gal solution (40 mM citric acid/sodium phosphate buffer,
pH 6.0, 5 mM potassium ferro cyanide, 5 mM potassium ferric cyanide,
150 mM NaCl, 2 mM MgCl2, and 1 mg/ml X-Gal) for up to 12 h, and ex-
amined under light microscope.
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